Vasospastic disorders of the digital circulation such as the Raynaud syndrome (RS) are known side effects of treatment of β-adrenergic blockade. The prevalence of RS in patients during treatment with β-blockers is not well defined. The objective of this meta-analysis is to assess the prevalence of RS in patients receiving β-blockers. A literature search was performed for studies dealing with RS and patients receiving β-blockers. The studies provided sufficient data to estimate the prevalence of RS in patients receiving β-blockers. A total of 13 eligible studies, contributing data on 1012 individuals, were included in this meta-analysis. For RS in patients receiving β-blockers, a pooled prevalence of 14.7% (95% confidence interval 0.076-0.236) were obtained. Statistically publication bias was not present (P = .877). Despite some heterogeneity, there is a possible indication of an association between RS and patients receiving β-blockers.
MarshallAJRobertsCJBarrittDW. Raynaud's phenomenon as side effect of beta-blockers in hypertension. Br Med J. 1976;1(6024):1498–1499.
5.
TaraziRCDustanHP. Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations. Am J Cardiol. 1972;29(5):633–640.
6.
VorburgerC. The anti-hypertensive effect of timolol maleate (blocadren) in gradated combination with a diuretic [in German]. Schweiz Med Wochenschr. 1976;106(43):1474–1481.
7.
RichardsS. Cutaneous side-effects of beta-adrenergic blockers. Australas J Dermatol. 1985;26(1):25–28.
8.
BolliPWaal-ManningHJSimpsonFOSeemanHM. Treatment of hypertension with labetalol. N Z Med J. 1977;86(602):557–563.
9.
HanssonLKarlbergBEAbergHWesterlundAJamesonSHenningsenNC. Long-term hypotensive effect of atenolol (ICI 66.082), a new beta-adrenergic blocking agent. Acta Med Scand. 1976;199(4):257–261.
10.
ZahaviIChagnacAHeringRDavidovichSKuritzkyA. Prevalence of Raynaud's phenomenon in patients with migraine. Arch Intern Med. 1984;144(4):742–744.
11.
12.
AxfordATGilchristL. Propranolol in the treatment of hypertension. Br J Clin Pract. 1971;25(7):326–328.
13.
HigginsJPThompsonSG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
14.
HigginsJPThompsonSGDeeksJJAltmanDG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
15.
DerSimonianRLairdN. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
16.
SchlattmannP. In: Medical Applications of Finite Mixture ModelsBerlin Heidelberg: Springer-Verlag; 2009.
17.
GalbraithRF. Graphical display of estimates having differing standard errors. Technometrics. 1988;30(3):271–281.
18.
EggerMDavey SmithGSchneiderMMinderC. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
19.
ThompsonSG. How should meta-regression analyses be undertaken and interpreted. Stat Med. 2002;21(11):1559–1573.
SchlattmannP.Finite Mixture Models and metaanalysis tools -based on C.A.MAN 0.64 [computer software]. 2008
22.
ZachariasFJCowenKJPresttJVickersJWallBG. Propranolol in hypertension: a study of long-term therapy, 1964-1970. Am Heart J. 1972;83(6):755–761.
23.
SteinerJACooperRMcPhersonKRileyAJ. Effect of beta-adrenoceptor antagonists on prevalence of peripheral vascular symptoms in hypertensive patients. Br J Clin Pharmacol. 1982;14(6):833–837.
24.
LiberatiAAltmanDGTetzlaffJ. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
25.
WeinrichMCMaricqHRKeilJEMcGregorARDiatF. Prevalence of Raynaud phenomenon in the adult population of South Carolina. J Clin Epidemiol. 1990;43(12):1343–1349.
26.
De AngelisRSalaffiFGrassiW. Raynaud's phenomenon: prevalence in an Italian population sample. Clin Rheumatol. 2006;25(4):506–510.
27.
SuterLGMurabitoJMFelsonDTFraenkelL. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum. 2005;52(4):1259–1263.
28.
ImmsFJNeameRLPowisDA. Responses of the cardiovascular system of the rat to noradrenaline infusions and their modification by adrenoceptor blocking agents. Br J Pharmacol. 1977;60(1):115–122.
29.
ChungMSGongHSBaekGH. Prevalence of Raynaud's phenomenon in patients with idiopathic carpal tunnel syndrome. J Bone Joint Surg Br. 1999;81(6):1017–1019.
30.
MaricqHRCarpentierPHWeinrichMC. Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison. J Rheumatol. 1997;24(5):879–889.
31.
HartmannPMohokumMSchlattmannP.The association of raynaud syndrome with thromboangiitis obliterans: a meta-analysis. Angiology. 2011
